SLRN Acelyrin
- 4.120
- +0.070+1.73%
- 4.000
- -0.120-2.91%
Acelyrin News
Piper Sandler Maintains Acelyrin(SLRN.US) With Buy Rating, Maintains Target Price $68
Piper Sandler analyst Yasmeen Rahimi maintains $Acelyrin(SLRN.US)$ with a buy rating, and maintains the target price at $68.According to TipRanks data, the analyst has a success rate of 34.3% and a to
Analysts Offer Insights on Healthcare Companies: ACELYRIN, INC. (SLRN), Arrowhead Pharmaceuticals (ARWR) and NovoCure (NVCR)
H.C. Wainwright Maintains Acelyrin(SLRN.US) With Buy Rating, Raises Target Price to $18
H.C. Wainwright analyst Emily Bodnar maintains $Acelyrin(SLRN.US)$ with a buy rating, and adjusts the target price from $16 to $18.According to TipRanks data, the analyst has a success rate of 37.3% a
ACELYRIN Price Target Raised to $18.00/Share From $16.00 by HC Wainwright & Co.
ACELYRIN Price Target Raised to $18.00/Share From $16.00 by HC Wainwright & Co.
HC Wainwright & Co. : The Acelyrin (SLRN.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $16.00 to $18.00.
HC Wainwright & Co. : The Acelyrin (SLRN.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $16.00 to $18.00.
Analysts Offer Insights on Healthcare Companies: Poseida Therapeutics (PSTX), Greenwich LifeSciences (GLSI) and ACELYRIN, INC. (SLRN)
HC Wainwright & Co. Maintains Buy on Acelyrin, Raises Price Target to $18
HC Wainwright & Co. analyst Emily Bodnar maintains Acelyrin (NASDAQ:SLRN) with a Buy and raises the price target from $16 to $18.
HC Wainwright & Co. Reiterates Buy on Acelyrin, Maintains $16 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates Acelyrin (NASDAQ:SLRN) with a Buy and maintains $16 price target.
Buy Rating Affirmed for ACELYRIN, INC. on Solid Financials and Promising Pipeline
ACELYRIN, INC.: Strong Buy Recommendation on Promising Izo Drug Prospects and Strategic Advancements
Acelyrin | 10-Q: Quarterly report
Calendar of U.S. Earnings Expected in the Week Ahead
Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc. Company Symbo
ACELYRIN Is Maintained at Buy by HC Wainwright & Co.
ACELYRIN Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Acelyrin, Lowers Price Target to $18
HC Wainwright & Co. analyst Emily Bodnar maintains Acelyrin with a Buy and lowers the price target from $28 to $18.
Analysts Conflicted on These Healthcare Names: Moderna (MRNA) and ACELYRIN, INC. (SLRN)
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), ACELYRIN, INC. (SLRN) and Moderna (MRNA)
Acelyrin Names Mina Kim as New Chief Executive Officer
ACELYRIN Founder Shao-Lee Lin Steps Down As CEO; Mina Kim Appointed As CEO And To Board
ACELYRIN Founder Shao-Lee Lin Steps Down As CEO; Mina Kim Appointed As CEO And To Board
Acelyrin Founder Steps Down as CEO
By Dean Seal Acelyrin founder Shao-Lee Lin has stepped down as chief executive and will be succeeded by the company's chief legal and administrative officer. The Los Angeles-based biopharmaceutical
ACELYRIN Gil Labrucherie, Chief Fincl Officer, Additionally Named Chief Business Officer >SLRN
ACELYRIN Gil Labrucherie, Chief Fincl Officer, Additionally Named Chief Business Officer >SLRN
Analysis
Price Target
No Data
